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Abstract
Cancer stem cells (CSCs) are self‐renewable cell types that are identified in most types
of liquid and solid cancers and contributed to tumor onset, expansion, resistance,
recurrence, and metastasis after therapy. CSCs are identified from the expression of
cell surface markers, which is tumor‐type dependent. The transition between CSCs
with cancer cells and other non‐CSCs occurs in cancers, which is possibly under the
control of signals from CSCs and tumor microenvironment (TME), including CSC niche.
Cancer‐associated fibroblasts are among the most influential cells for promoting both
differentiation of CSCs and dedifferentiation of non‐CSCs toward attaining a CSC‐like
phenotype. WNT/β‐catenin, transforming growth factor‐β, Hedgehog, and Notch are
important signals for maintaining self‐renewal in CSCs. An effective therapeutic
strategy relies on targeting both CSCs and non‐CSCs to remove a possible chance of
tumor relapse. There are multiple ways to target CSCs, including immunotherapy,
hormone therapy, (mi)siRNA delivery, and gene knockout. Such approaches can be
designed for suppressing CSC stemness, tumorigenic cues from TME, CSC extrinsic
and/or intrinsic signaling, hypoxia or for promoting differentiation in the cells. Because
of sharing a range of characteristics to normal stem/progenitor cells, CSCs must be
targeted based on their unique markers and their preferential expression of antigens.
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1 | INTRODUCTION
Tumors (solid and liquid) are composed of a large number of bulk
cancer cells along with a small population of cancer stem cells (CSCs)
(Marquardt, Solanki, Spitschak, Vera, & Pützer, 2018; Takebe, Harris,
Warren, & Ivy, 2011). CSCs are a group of quiescent self‐renewing
cell types pre‐exist in primary cancers and localized within the tumor
niches bearing enriched functional potential to drive cancer growth,
to reconstruct their heterogeneity (Batlle & Clevers, 2017; Lytle,
Barber, & Reya, 2018) and so to make variations in cancer
regenerative capacity (Visvader & Lindeman, 2008). The cells have
the capacity to generate in vitro clones and to reform cancers after
their transplantation into immunodeficient animals (Golan et al.,
2018). CSCs were first defined as a subpopulation of cancer cells that
can expand the pool of CSCs and differentiate into progenitor cancer
cells via symmetric and asymmetric divisions (Baumann, Krause, &
Hill, 2008). Since their first identification in human acute myeloid
leukemia (AML), CSCs have been harvested from most of the solid
tumors and malignancies of hematopoietic origin (Dean, Fojo, &
Bates, 2005; D. Zhang, Tang, & Rycaj, 2018), and their tumorigenic
activity is attested in several cancers, including brain, liver, lung,
colon, breast, ovarian, pancreas, prostate, melanoma, head and neck,
and bladder (Takebe et al., 2011). The frequency of CSCs increases
upon tumor progression (D. Zhang et al., 2018) and is seemingly
different from one cancer to another (Visvader & Lindeman, 2008).
The concept of CSC derives from the fact that tumors are considered
as dysregulated tissue clones that their constant propagation is
vested in a distinct subset of cell types called CSCs (Nguyen, Vanner,
J Cell Physiol. 2018;1-15. wileyonlinelibrary.com/journal/jcp © 2018 Wiley Periodicals, Inc. | 1
Dirks, & Eaves, 2012). The term “cancer stem cell” is reflective of the
stem‐like features and the potential of the cells to sustain
tumorigenesis constantly (Visvader & Lindeman, 2008). Other terms
used for these cells (in addition to CSCs) from research studies are
“tumor rescuing units,” “tumor‐progenitor cells,” “functional tumor
stem cells,” “cancer‐stem‐like cells,” “tumor‐propagating cells” and
“tumor‐ or cancer‐initiating cells” (Baumann et al., 2008; Dianat‐
Moghadam et al., 2018). The term cancer‐initiating cells is used
because of the ability of the cells to generate a progressively growing
cancer that consists of cells resembling those in the original tumor
(Nguyen et al., 2012).
There are three implicit origins for CSCs: (a) (epi)genetic changes
like methylation, demethylation, mutations, and rearrangement in the
stem/progenitor cell pool (niche) or even in differentiated cells; (b)
spontaneous oncogenic reprogramming in somatic cells; and (c) tumor
microenvironment (TME) activation through providing extracellular
cues (Dianat‐Moghadam et al., 2018). CSCs usually share many of their
defining features with normal stem cells, including relative quiescence,
active DNA repair systems, aggressive proliferation, and drug resistance
(Batlle & Clevers, 2017; Dean et al., 2005; Lytle et al., 2018). Their
multipotent characteristic has also been identified for cancers, such as
glioblastoma (Gilbertson & Rich, 2007). These features are considered
as a possible reason for higher incidence of cancer development in
tissues enriched in stem cells (Jaeckel et al., 2018) in which mutation in
the stem‐like cells is more potent for generating cancers than mutations
in other more differentiated cell types, reported in colon cancer
(Jaeckel et al., 2018). Subventricular zone in the brain, for instance,
exhibits a high degree of cell proliferation, and it seems that this region
is one of the anatomical origins for brain CSCs (Vescovi, Galli, &
Reynolds, 2006). Functional properties of the stem cells during cancer
expansion and responses to the therapeutic approaches is defined by
TME (Lenos et al., 2018) that plays important roles in development and
progression of tumor (Goto et al., 2018).
The cellular transition between CSCs with cancer cells and other
non‐CSCs has received too much attention recently (Z. Liu et al.,
2018). Mutations in normal stem cells is responsible for dysregula-
tion of their self‐renewal and further transformation of the cells into
CSCs (Pardal, Clarke, & Morrison, 2003). These mutated CSCs have
increased proliferation, reduced apoptosis, and enhanced immune
evasion capacity resulting in expansion of the stem cell compartment,
which is a typical feature of malignant tumors (Dean et al., 2005). The
ongoing mutagenesis is responsible for the generation of diverse
phenotypes of cancer cells from CSCs (Pardal et al., 2003).
CSCs have the ability to xenograft cancer and differentiate into a
number of heterogeneous population of cells, which is for maintain-
ing and propagating cancers (Medema & Vermeulen, 2011; Nakano
et al., 2018). CSCs have extensive proliferative potential to
regenerate a tumor and form disseminated metastatic tumors,
whereas the cancer cells derived from them have limited proliferative
and regenerative capacity, thereby forming limited benign tumors
(Dean et al., 2005; Pardal et al., 2003). The diverse proliferative
capacity between the two cell types was the basis for proving the
existence of CSCs at first in the context of AML (Pardal et al., 2003).
CSC targeting for cancer therapy is considered as an interesting
area of current research, and killing of the cells is thought to be an
essential component of efficient antitumor therapies (Medema,
2017). CSCs are needed to be removed in order for cancer‐targeted
therapy to be curative. In fact, even a single CSC can theoretically
capable of reconstituting an entire tumor (Hermann & Sainz, 2018).
There are still too much complexities regarding the actual identity of
the cells, their precise location within a tumor and established ways
of targeting them. Improving the understanding about the character-
istics of CSCs and signaling mediated by them would help to develop
more compatible therapeutic approaches for targeting these cells. To
write this review, we intended to focus on CSCs and their implication
in the initiation and progression of tumor. CSCs are highly plastic
cells with diverse origins and are known as the leader cells
contributed to the failure of chemo/radiotherapy. The review
provides knowledge about CSC plasticity, identification, functioning,
cross‐talking, and related signaling. Then, we will place the knowl-
edge harvested from the review in the context of therapeutic
approaches. The primary aim of the therapeutic approaches is to
sensitize CSCs to respond to such strategies. Then, these protocols
are needed to be completed by targeting secondary intriguing factors
responsible for the enrichment of the CSCs within their niche.
PubMed database was searched to find relevant articles. The criteria
for article selection was based on the quality of journals, the novelty
of subjects and the number of citations per year for relevant articles.
More than 500 papers were scanned for this review by searching
the keywords “cancer stem cells” and “cancer,” among them
approximately 100 papers have pursued the criteria for further
interpretation.
2 | PLASTICITY OF CSCs (STEMNESS,
DIFFERENTIATION, AND
DEDIFFERENTIATION)
CSCs share features similar to tissue‐resident stem cells, including
self‐renewal, quiescence, and differentiation (D. Zhang et al., 2018).
Like tissue‐resident cells, CSCs follow two ways of divisions:
symmetric and asymmetric. In the symmetric division, every stem
cells divide invariably to create one daughter cell and one new stem
cell, whereas in the asymmetric division, the cells depending on the
space available in the niche can possibly create a diverse number of
new cells, may be zero, one, or two in number. Normally, there is a
balance between symmetric and asymmetric divisions, which is for
restricting cancer progression or for diverting tumors from high to
low grade. Upon tumorigenesis, however, there is a shift toward
enhanced symmetric division (renewal), leading to the expansion of
CSC fraction that subsequently drives a more vigorous and
undifferentiated state in cancers (progression from low to high‐
grade cancer). Therefore, an increase in the asymmetric division can
be served as an approach to halt the aggressive progression of cancer
(Batlle & Clevers, 2017; Lytle et al., 2018). The nearby committed
cells within the niche send signals to the stem cells to keep their
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stemness and to restrict their differentiation. The point here is that
both CSCs and the nearby non‐CSCs are plastic, and depending on
the environmental cues they receive, the two types of cells could
attain self‐renewal capacity and are able to be tumorigenic even
equally (Batlle & Clevers, 2017). The plasticity of CSCs is also
dependent on tumor type and cell context (Gao et al., 2018). The
importance of this point is for therapeutic designing strategies in
which a prolonged success will be expected only when both non‐
CSCs and CSCs are targeted, not just CSCs.
In the context of cancer, there is a large and exclusive association
between plasticity mostly with CSCs, while in non‐CSCs this plastic
feature is considerably restricted. However, under some circum-
stances, non‐CSCs can replenish the CSC population (Hermann &
Sainz, 2018). CSCs have the capacity to differentiate into non‐CSCs
(Nakano et al., 2018). Dedifferentiation is a process by which non‐
CSCs even in a complete differentiated state can retain their tumor‐
initiating capacity by replacing the either lost CSCs or cancer cells
(Batlle & Clevers, 2017; Chaffer et al., 2011). For example, CSC‐like
properties of breast cancer cells is reported to be potentiated after
exposure of the cells to the adipsin derived from mammary‐adipose‐
derived stem cells (Goto et al., 2018). Stemness‐related genes can
also be activated in cancer cells to exhibit CSC‐like properties. Oct4,
sex determining region y‐box 2 (Sox2), Nanog, CD44 (also called
PGP1), CD133 (also called PROM1), and ABCG2 are examples of
these genes (Cao et al., 2018; Dianat‐Moghadam et al., 2018). For
example, upregulation of Sox2 in lung cancer cells could enhance
expression of pluripotent factors OCT4 and Nanog in the cells and
drives them toward a CSC‐like phenotype (Ooki et al., 2018).
Interleukin 6 (IL‐6) released from CSCs is responsible for keeping a
dynamic equilibrium between the cells with non‐CSCs, shown in
breast and prostate cancer (Iliopoulos, Hirsch, Wang, & Struhl, 2011).
Epithelial–mesenchymal transition (EMT) has been identified as
one of the important mechanisms controlling CSC biology (D. Zhang
et al., 2018). The importance of this is in a report that cells with
increased rates of EMT plasticity and mobility are known as CSCs
(Marquardt et al., 2018). EMT is also a mechanism for the acquisition
of a CSC‐like phenotype in non‐CSCs (C. Chen et al., 2018). During the
EMT, epithelial cells would lose their polarity and cell‐to‐cell contact to
acquire motility and invasiveness (Ji et al., 2018). TWIST1 and SNAI1
(Snail) are master regulators of EMT and the key genes for inducing
dedifferentiation of non‐CSCs toward a CSC‐like state (Batlle &
Clevers, 2017; Nakano et al., 2018). TWIST1 mediates this process in a
mechanism dependent or independent on EMT (Nakano et al., 2018).
ZEB1 is another key regulator of the EMT that its activation by
transforming growth factor‐β (TGF‐β) in non‐CSCs could switch them
to the CSC state (Chaffer et al., 2013). TGF‐β inducible effects on EMT
is also carried out by reduction of the rate for ferritin heavy chain
(FTH‐1) that is known as a negative regulator of CSC expansion and
EMT. Iron trafficking in CSCs has shown to be more robust than other
cells within a tumor, which is for the promotion of CSC enrichment (El
Hout, Dos Santos, Hamaï, & Mehrpour, 2018). CSCs like other stem
cells have mesenchymal‐like phenotype (Batlle & Clevers, 2017). This
phenotype can be reactivated in cancer cells through expression of
specific transmembrane proteins (ex, glycoprotein nmb) on the surface
of the cells (C. Chen et al., 2018) or induction of the EMT‐related
transcription factors. This reactivation can facilitate migratory and
invasiveness features of the CSC‐like cells. These migratory cells when
reached to the target metastatic organ probably reprogram again
toward their primary cells by silencing EMT mediators. This EMT
programming is apparently different in CSCs compared with stem cells
within the normal tissue (Batlle & Clevers, 2017). In Figure 1, the
plasticity of CSCs for differentiation and the capacity of non‐CSCs
like cancer cells for dedifferentiation toward attaining a CSC‐like
phenotype has been clarified.
3 | IDENTIFICATION OF CSCs
CSCs are highly plastic and hidden in tumors that hinder their easy
identification and eradication. Their identification is generally based on
cell surface marker expression (Dianat‐Moghadam et al., 2018).
Evaluation of the rate of expressions for related genes and protein
signature in CSCs is reflective of their density in patient’s tumor
tissues (Marquardt et al., 2018). CD24, CD26, CD44, CD133, CD166,
aldehyde dehydrogenase (ALDH) and Ep‐CAM (also called CD326 or
epithelial‐specific antigen/ESA) are examples of CSC‐specific surface
markers (Dianat‐Moghadam et al., 2018). CD24, CD34, CD44, CD166,
CD133, and ALDH1 are used to identify CSCs in solid tumors (da Silva‐
Diz, Lorenzo‐Sanz, Bernat‐Peguera, Lopez‐Cerda, & Muñoz, 2018).
One of the key functions of the CSC surface markers is to mediate
adhesion of the cells to their niche. Examples of such markers are
CD29 (β1‐integrin), CD44, CD133, CD166, and EpCAM (De Robertis,
Poeta, Signori, & Fazio, 2018). ALDH1 is a NAD(P)‐dependent enzyme
responsible for the oxidation of aldehydes in an intracellular milieu
into carboxylic acids, and it is related to the tumorigenic and
metastatic features in CSCs (Bai, Ni, Beretov, Graham, & Li, 2018).
Expression of the surface markers in the CSCs is different from
other cells within the tumor tissue (Batlle & Clevers, 2017). The
stem/progenitor cells are often the origins for cancer cells and would
pass on their phenotypical traits to the cancer cell population,
especially to the CSCs (Comoglio, Trusolino, & Boccaccio, 2018).
Thus, expression of stem cell specific markers in an unrelated organ
can be exploited for identifying the cells (Batlle & Clevers, 2017). For
example, B‐lymphoma moloney murine leukemia virus insertion
region‐1 (BMI1) is required for self‐renewal of both CSCs and
normal stem/progenitor cells (Goto et al., 2018). CD133+ CSCs are
found in cancers like glioblastoma, ependymoma, lung, and colorectal
cancer (CRC; Baumann et al., 2008; Cao et al., 2018; Gilbertson &
Rich, 2007), CD44+ CSCs are found in cancers like breast cancer
(Gilbertson & Rich, 2007). In the brain, CD133 is used as both a
marker for identifying normal neural precursors in human and for the
enrichment of CSCs (Vescovi et al., 2006). Oligodendrocyte lineage
transcription factor 2 (OLIG2) promotes proliferation of both CSCs
and neural progenitor cells in glioblastoma (Gilbertson & Rich, 2007).
A point is that although CSCs exhibit markers of normal stem cells on
their surface, the process of glycosylation of these cell surface
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markers is different in CSCs compared with that in normal stem cells
(De Robertis et al., 2018). Some markers are inherited in CSCs in
association with their tumorigenic potential. These are called
“oncogene inherited” markers. Tumors with active mutations of
RAS pathway often harbor the oncogenic drivers. An example of such
markers is MET, so the wide‐spread expression of such markers in
tumors can be interpreted as the expansion of CSCs with stem and/
or progenitor features (Comoglio et al., 2018). Markers identified for
CSCs has been described in Figure 2, and cancer‐dependent
expression of markers in CSCs has been shown in Table 1. The point
here is that some markers are specific for the cells and others are
not. This diversity is dependent on the type of tumor, so the
expression of one marker in a type of tumor may exceed the others.
An example of such markers is leucine‐rich repeat‐containing G
protein‐coupled receptor 5 (Lgr5). Lgr5 is an intestinal stem cell
marker that is expressed in CSCs harvested from patients with colon
cancer and animal models (Lenos et al., 2018; Medema, 2017), and its
expression is associated with the clonogenic features (Lenos et al.,
2018) and production of progeny that undergo progressive differ-
entiation but with slower kinetics compared with their nontrans-
formed counterparts. This marker, however, is not so detrimental for
CSC identification, as it has been reported that only a small number
of adenoma cells that stained positive for this marker act as CSCs
(Batlle & Clevers, 2017). Flow cytometry‐dependent functional
F IGURE 1 Cancer stem cell (CSC) plasticity. CSCs can be differentiated into cancer cells. Cancer cells, in turn, receive signals from tumor
microenvironment (TME) to dedifferentiate into CSCs. Cancer‐associated fibroblasts (CAFs) are the key cells in directing CSC plasticity through
promoting cancer cell dedifferentiation and providing a supportive niche (constructed from fibrillary collagens) for their colonization and
chemoresistance features. This niche also contains vascular bed constructed by a cooperation work between CSCs and CAFs. Hepatocyte
growth factor (HGF) derived from CAFs stimulates WNT signaling in cancer cells for further promotion of their dedifferentiation. CSCs release
interleukin (IL)‐6 to keep a dynamic equilibrium between differentiation and dedifferentiation of the cells. The release of transforming growth
factor‐β (TGF‐β) and fibroblast growth factor 5 (FGF5) from CAFs induces myofibroblast reprogramming in the CSCs for metastatic purposes.
From these myofibroblastic cells, fibronectin (FN) is released to sustain the reprogramming process. CXCL12: CXC motif ligand 12; EMT:
epithelial–mesenchymal transition; VEGF: vascular endothelial growth factor
F IGURE 2 Cancer stem cell (CSC) identity. CSCs can be
recognized through the expression of markers on their surface.
Expression of the markers can be specific for one type of cancer but
not for others. Leucine‐rich repeat‐containing G protein‐coupled
receptor 5 (Lgr5) is an example of these markers that is specific for
intestinal cancers. BMI1: B‐lymphoma moloney murine leukemia
virus insertion region‐1; Sox2: sex determining region y‐box 2
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assays can be applied as an alternative approach for the identification
of CSCs (Takebe et al., 2011). For example, flow cytometry tracing of
the enzymatic activity for ALDH1 can be used as a specific marker
for identification and isolation of colon CSCs, as this marker directs
their maintenance and propagation (Dianat‐Moghadam et al., 2018;
E.H. Huang et al., 2009).
4 | CSC‐RELATED SIGNALING
CSCs utilize many of the same signaling pathways found in normal stem
cells that are called developmental signaling, including WNT, Notch, and
Hedgehog (Hh; Marquardt et al., 2018; Takebe et al., 2011). TGF‐β along
with phosphoinositide 3 kinase (PI3K)/AKT, STAT or EGFR are oncogenic
cascades in CSCs (Marquardt et al., 2018). In Figure 3, a concise overlook
toward signaling related to CSC tumorigenic features has been shown.
Below a number of the key signaling pathways are presented.
4.1 | Transforming growth factor‐β
TGF‐β is a differentiation signal, and the general concept may
possibly be that this growth factor is downregulated in stem cells
within their niche (Batlle & Clevers, 2017). TGF‐β through activation
of EMT‐inducing transcription factors could promote conversion of
cancer cells toward a CSC‐like state. This activation occurs through
TGF‐β inducible effects on other signaling including ERK and
PI3K/AKT (Mortezaee, 2018; Najafi, Salehi et al., 2018; Nakano
et al., 2018). TGF‐β is also important for sustained expression of
master stem cell state regulators, namely blocker of DNA binding (ID)
regulators (Comoglio et al., 2018). ID regulators are transcriptional
regulators that are frequently regulated in most of the human
cancers. Accumulation of ID4 is contributed to stemness phenotype
in breast cancer, and knockdown of ID1, ID2, and ID4 in mice glioma
is associated with impaired CSC properties (Lasorella, Benezra, &
Iavarone, 2014).
TABLE 1 Cancer stem cell (CSC) markers in various cancers
Type of cancer Markers References
Breast CD44 and CD133 Bai et al. (2018)
CRC CD24, CD29, CD44, CD51, CD133, CD166,
Lrg5, Sox2, EpCAM, and BMI1
De Robertis et al. (2018); Medema and Vermeulen (2011); Sui et al. (2018);
Visvader and Lindeman (2008); Wang, Fu, Sun, Guo, & DuBois (2015)
Glioblastoma CD133, nestin, and A2B5 Gilbertson and Rich (2007); Haspels et al. (2018)
Lung CD44, CD133, CD166, and EpCAM Cao et al. (2018); Visvader and Lindeman (2008); Zakaria, Mohd Yusoff, Zakaria,
Widera, & Yahaya (2018)
Ovary CD44 and CD133 C. Liu et al. (2011); Xiang et al. (2015)
Pancreas CD44 and CD133 C. Liu et al. (2011); Visvader and Lindeman (2008))
Prostate CD44, CD51, and CD133 Sui et al. (2018); Visvader and Lindeman (2008)
Ependymoma CD133 and nestin Gilbertson and Rich (2007)
AML CD34 Nguyen et al. (2012)
Skin CD34 Malanchi et al. (2008)
HCC CD44, CD90, CD133, and EpCAM Gao et al. (2018); Visvader and Lindeman (2008); Yoshida (2018)
Bladder CD44 C. Liu et al. (2011)
Gastric CD44 Ji et al. (2018)
Note. AML: acute myeloid leukemia; CRC: colorectal cancer; HCC: hepatocellular carcinoma; Sox2: sex determining region y‐box 2.
F IGURE 3 Cancer stem cell (CSC)
related signaling. Transforming growth
factor‐β (TGF‐β), Hedgehog (Hh), Notch,
and WNT/β‐catenin are dominant signaling
in promoting stemness of CSCs. EGF:
epidermal growth factor; FGF: fibroblast
growth factor; FGFR, fibroblast growth
factor receptor; MEK, mitogen‐activated
protein kinase kinase
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4.2 | WNT/β‐catenin
WNT signaling is for keeping self‐renewal in both CSCs and non‐CSCs
maintaining them in an undifferentiated state, so activation of WNT
signaling is associated with the initiation of cancer (Batlle & Clevers,
2017). WNT/β‐catenin along with Notch pathway is activated by
activating protein‐4 (AP4) for increasing the number of CSCs and
regulating their homeostasis, as shown for colon cancer (Jaeckel et al.,
2018). β‐catenin signaling is important for maintaining the CSC
phenotype, as reported in skin cancer (Malanchi et al., 2008), and
stemness (Wu et al., 2018). Overexpression of Rap1 interacting factor
1 (RIF1) (a positive regulator of the WNT/β‐catenin pathway) induces
cell cycle progression to exhibit CSC‐like properties in lung cancer
cells (Mei, Liu, Cao, Tian, & Zhou, 2018). Mechanism of action of other
factors like Forkhead box C1 (FOXC1) for inducing CSC‐like proper-
ties is through upregulation of β‐catenin in lung cancer cells (Cao et al.,
2018). β‐catenin is also the main contributor of high metastatic
capacity, a characteristic of CSCs (Cao et al., 2018). A switch in the
WNT to Hh is associated with progression of CSCs toward metastasis
(Medema & Vermeulen, 2011). In addition, activation of the WNT
signaling in cancer cells mediated by hepatocyte growth factor (HGF)
released from cancer‐associated fibroblasts (CAFs) is contributed to
the promotion of cancer cell dedifferention into CSCs (Comoglio et al.,
2018; Medema & Vermeulen, 2011).
4.2.1 | MEK
RAS mediated activation of Raf–MEK–ERK is cardinal for promoting
CSC proliferation. CD276 (B7‐H3) is a tumor‐promoting glycoprotein
overexpressed in CSCs. CD276 through activation of MEK can
increase the size of CSC pool (Z. Liu et al., 2018).
4.3 | Notch
As mentioned, Notch pathway is related to the sustained self‐renewal
capacity of CSCs. Notch is activated by factors like IL‐6 released by
both CSCs and CAFs (Bai et al., 2018), and its suppression using
antibody against its ligand delta‐like ligand 4 (Dll4) in CRC has shown a
reduction in the frequency of CSCs, a delay in tumor recurrence, and
a decrease in the rate of metastasis (Hoey et al., 2009). Notch is also a
promoter of CSC survival approved for breast cancer (Shah et al.,
2018). Notch inhibitory effect on phosphatase and tensin homologue
(PTEN) is necessary for the promotion of survival in such cancer. In
addition, Notch promotes apoptotic resistance in CSCs possibly
through activation of nuclear factor of κB (NF‐κB) (Baker et al., 2018).
4.4 | Hedgehog
The Hh signaling is related to stem cell maintenance during
embryonic development, and its hyperactivation can cause tumor-
igenesis in a variety of organs (Takebe et al., 2011). BMI1 as a self‐
renewal marker of CSCs (Goto et al., 2018) is a downstream target of
the Hh signaling (Takebe et al., 2011).
Presentation of the signaling mentioned above is not mean that
the other signaling pathways activated in CSCs are not important for
influencing their tumorigenesis. We just presented signaling path-
ways that are more general for most of the cancer types. It is
important to take into account other important signaling pathways in
relation to cancer, such as EGFR, STAT, NF‐κB, and PI3K/AKT. For
example, The PI3K/AKT and its engagement with mammalian target
of rapamycin (mTOR) is reported to be in association with enhanced
EMT/CSC phenotype (Chang et al., 2013) important for shaping a
metastatic feature in the newly formed CSCs. Activation of NF‐κB
signaling in lung cancer is reported to induce apoptotic resistance
and EMT in CSCs (Zakaria et al. , 2018).
5 | CSC FUNCTIONING AND
CROSS ‐TALKING WITHIN THE TME
CSCs are reported to be responsible for sustained long‐term tumor
growth (Batlle & Clevers, 2017), metastasis to distant organs (Cazet
et al., 2018), and an inevitable recurrence of cancer after chemo‐
and/or radiotherapy (Batlle & Clevers, 2017). CSCs express gene
signature related to EMT, so the capacity of cancer to propagate and
migrate into distant sites is considered as a silent feature of CSCs
(Lytle et al., 2018). In addition, DNA mutations and TME factors
possibly drive CSCs toward a metastatic phenotype (Takebe
et al., 2011).
Recent progress in the recognition of the CSC phenotypic and
molecular features and their cross‐talking with the TME could
provide a huge benefit for the development of CSC‐based therapies
and radical improvement in prevention of metastasis and prognosis
of patients with cancer (Marquardt et al., 2018). There is no doubt
that TME can spatially and temporally influence cancer cells and
CSCs through complex cross‐talking in a form of cell‐to‐cell contacts
and secreted factors. Differentiated cancer cells upon exposure to
the right microenvironment can retain characteristics of CSCs
(Medema & Vermeulen, 2011). Cross‐talking between CSCs with
cells within the TME is dynamic and complex and encompass
interactions between CSCs with tumor stromal cells and other non‐
CSCs. It is believed that CSCs reside in a smaller specialized TME
subcompartment niche called CSC niche. This niche basically contains
cellular and noncellular components similar to that present within
the TME, including CAFs, endothelial cells (ECs), immune cells, such
as tumor‐associated macrophages (TAMs) as well as ECM. The TME
and its CSC niche are different in each tumor type (Hermann & Sainz,
2018; D. Zhang et al., 2018). CSCs can alter cellular activity within a
hypoxic TME for tumorigenic purposes. Interactions between CSCs
with other stromal cells can be determined using three‐dimensional
culture systems (Goto et al., 2018).
5.1 | Cancer‐associated fibroblast
CAFs are the main actors for shaping cancer biology, and high
number of cells within a tumor is related to weak prognosis and
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therapy resistance (Cazet et al., 2018). CSCs reside predominantly at
the tumor edge in the close proximity to the CAFs (Lenos et al.,
2018). CAFs are involved in dedifferentiation of cancer cells. This is
possibly occurring through secretion of TGF‐β from the cells. CAFs
provide a mechanical supportive niche for the newly formed CSCs
(from cancer cell dedifferentiation), which is for protecting the cells
from outside influences, and thereby acquisition of a chemoresis-
tance feature in the cells (Figure 1). To do this, CAFs would respond
to Hh ligand produced by cancer cells for expression of fibroblast
growth factor 5 (FGF5) and formation of fibrillary collagen. Increase
in collagen content within the stroma is also correlated to the
stemness and CSC properties of cancer cells. The FGF5 ligand
expressed by CAFs interacts with FGFR in CSCs for mediating their
stemness and chemoresistance (Cazet et al., 2018). Interestingly,
CSCs have the capacity to transform into CAFs, which is for
mimicking CSC niche formation. This transformation is mediated by
TGF‐β released from CAFs (Dianat‐Moghadam et al., 2018). Activa-
tion of the FGFR signaling in CSCs initiates myofibroblast repro-
gramming of the cells. The reprogrammed cells could promote CSC
metastatic features, and they release fibronectin to sustain the
fibrogenic reprogramming of the CSCs (W. Zhang et al., 2018). CAFs
also release HGF to replace FGF in sustaining long‐term propagation
of CSCs (Comoglio et al., 2018; Figure 1). In addition, CAFs secrete
factors such as osteopontin (OPN) for regulation of CSC clonogeni-
city (Lenos et al., 2018). Moreover, CAFs release CXC motif ligand
12 (CXCL12; also called Stromal‐cell‐derived factor‐1) that through
interaction with its receptor CXCR4 expressed on the surface of
CSCs could facilitate migration of CSCs to the metastatic sites (Bai
et al., 2018; Farhood, Najafi, & Mortezaee, 2018). IL‐6 is produced by
both CAFs and CSCs acting in the promotion of CSC stemness,
expansion, and survival (Lytle et al., 2018). IL‐6 release to the TME
also favors CAF growth (Bai et al., 2018).
5.2 | Endothelial cells
CSCs possibly have strong angiogenic features and are contributed to
the recruitment of vessels during tumorigenesis (Gilbertson & Rich,
2007). CSCs anchored to their niche receive supportive signals via cell‐
to‐cell contacts with ECs within the blood vessels (Lasorella et al.,
2014). Glioblastoma CSCs under the influence of TGF‐β are able to
give rise to pericytes for supporting neovascularization and cancer
growth (Cheng et al., 2013). CSCs secrete angiogenic factors vascular
endothelial growth factor (VEGF) and CXCL12 to accelerate angiogen-
esis in ECs (Dianat‐Moghadam et al., 2018). ECs, in turn, secrete
factors such as nitric oxide (NO) and the CD44 ligand OPN for
maintaining stem cell traits (stemness) in CSCs. NO can promote
Notch signaling in the cells. Interestingly, inhibition of ECs using anti‐
VEGF therapy can also be tumorigenic. A possible reason is that the
anti‐VEGF therapy can induce hypoxia within the TME that surpris-
ingly induce VEGF within the TME in a negative feedback loop
(Gilbertson & Rich, 2007; Lytle et al., 2018). This hypoxic milieu can
also block CSC differentiation (Lytle et al., 2018), increase therapy
resistance of the cells (Baumann et al., 2008), and promote stem‐like
features in non‐CSCs (Lytle et al., 2018). In addition, ECs upregulate
transmembrane protein capillary morphogenesis gene 2 (CMG2) to
promote stemness, invasion and metastasis of CSCs by activation of
the WNT/β‐catenin pathway shown in gastric cancer (Ji et al., 2018).
There are other cells within the TME taking important cross‐
talking with CSCs for progression of their tumorigenicity. There is a
positive feedback loop of interaction between CSCs with M2 cells in
which CSCs secrete TGF‐β to stimulate M2 cells for secreting IL‐37
that, in turn, potentiates self‐renewal, pluripotency, and invasive
features of CSCs, as shown in pancreatic cancer (Sainz et al., 2015).
Likewise, CSCs secrete interferon‐β to stimulate M2 cells for secretion
of interferon‐stimulated gene 15 (ISG15) that, in turn, reinforces self‐
renewal and invasiveness features of CSCs (Sainz, Martín, Tatari,
Heeschen, & Guerra, 2014). CSCs also promote the education of
monocytes and/or macrophages toward TAMs. The IL‐6/signal
transducer and activator of transcription 3 (STAT3) signaling facilitates
cross‐talking between CSCs and TAMs (H. Huang et al., 2018).
Natural killer (NK) cells are the key immune cells for killing CSCs
by targeting the cells showing no or low rate of expression for major
histocompatibility complex class I (Anja, Anahid, & Janko, 2018).
CSCs are possibly more sensitive to the NK‐mediated lysis than
differentiated cells, evidenced for glioblastoma (Haspels, Rahman,
Jospeh, Navarro, & Chekenya, 2018). NK cells also limit the
expansion of regulatory T lymphocytes (Tregs; Anja et al., 2018).
Tregs have essential bidirectional cross‐talking with CSCs for the
promotion of an aggressive behavior in tumors. Upregulation of IL‐4
in CSCs favors release of TGF‐β to the TME for promoting Treg and
myeloid‐derived suppressor cell generation. IL‐4 could directly impair
the activity of cytotoxic T lymphocytes (CTLs; D. Zhang et al., 2018)
and induce M2 polarization (Tzeng et al., 2018). In addition, IL‐6
release from CSCs is important not only for sustaining their stemness
(self‐renewal) but also for activating Tregs, inactivating CTLs and
inducing macrophage polarity toward a protumor M2‐like phenotype
(L. Chen et al., 2018; Kato et al., 2018; Lytle et al., 2018; Su et al.,
2018). A hypoxic TME facilitates IL‐6 release from CSCs by
increasing the rate of expression for adenosine within the TME
(Lan et al., 2018). Adenosine has been identified as a potent
proinvasive factor (Siriwon et al., 2018), and it is a strong stimulator
of Treg immunosuppressive activity (Ghalamfarsa et al., 2018) and a
suppressor of CTLs (Y. Liu et al., 2018). Cross‐talking between CSCs
with other cells within TME has been shown in Figure 4.
6 | CSC TARGETING IN CANCER THERAPY
6.1 | CSC resistance to chemo/radiotherapy
CSCs are essentially account for tumor relapse (recurrence), drug
resistance, and metastasis to standard chemo/radiotherapy (Batlle &
Clevers, 2017), which are the principal causes of poor survival in
affected patients (Z. Liu et al., 2018). The first two features are
common among CSCs harvested from tissues of diverse origins (Anja
et al., 2018). The preferential targets for chemo/radiotherapy are non‐
CSCs that make up the bulk of cancer exhibiting transient (limited)
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proliferative rates and are not responsible for long‐term tumor growth
(Batlle & Clevers, 2017; Hermann & Sainz, 2018). There is evidence
that residual tumors are frequently enriched with CSCs, so the cells
are essentially responsible for tumor rebound after therapy (Cazet
et al., 2018). CSCs remain in a quiescent state under treatment (Bai
et al., 2018), which is a possible reason for more resistant nature of
these cells to the targeted therapy (Visvader & Lindeman, 2008). CSCs
usually reside far from cancer vessels, so the cells are not easily
targeted using nanoparticle delivery of drug agents (Zuo et al., 2016).
Even they are under exposure to drugs, they have efficient modalities
to take less influential from these agents. CSCs express ATP‐binding
cassette (ABC) transporters acting as unidirectional cellular pumps
that at high levels could cause resistance of the cells to chemother-
apeutic drugs through increasing drug efflux, and thereby attenuating
the amount of drugs accumulated within the cells (Dean et al., 2005;
Dianat‐Moghadam et al., 2018; Takebe et al., 2011). ABCG2 is an
example of the ABC transporters expressed in CSCs, and it could be
considered as an independent marker for isolation of CSCs (Bai et al.,
2018). CSCs highly express antiapoptotic genes, such as BAX, BCL‐2
and BIRC5, that cause resistance of these cells to apoptotic signals
(Zakaria et al., 2018). The phenotypic transition may also occur in
CSCs. This transition could cause changeable signaling patterns and
markers in the cells reducing the efficacy of therapy (Bai et al., 2018).
The resistance of CSCs to radiation therapy is another concern. The
rate of resistance is differing from one tumor to another, thereby
influencing radiocurability of tumors (Baumann et al., 2008). CSCs
express high levels of free‐radical scavengers to reduce intracellular
reactive oxygen species levels generated after radiotherapy (Takebe
et al., 2011), thereby high doses of radiation are possibly required for
targeting the cells (Baumann et al., 2008). The high rate of expression
for ALDH and resistance‐associated proteins, and uncontrolled activity
of DNA repairing are other reasons for CSC resistance to treatment
(Bai et al., 2018; Dianat‐Moghadam et al., 2018). Constitutive
activation of DNA damage response in CSCs could cause resistance
to radiotherapy (Carruthers et al., 2018). Taken together, this
information indicates that by application of the conventional
chemo/radiotherapy we could not expect to observe a curable tumor
demanding a combination of other approaches for targeting CSCs in
more specific ways. Mechanisms of CSC resistance to therapy is
summarized in Figure 5. An anticancer approach can cure cancer only
if all CSCs are killed (Baumann et al., 2008). This is not applicable
unless exploiting a combination of agents that have selective toxicity
to CSCs with agents suppressing the bulk non‐CSC populations or
blocking conversion of non‐CSCs to CSCs. This combination is
important because (as aforementioned) after cessation of therapy,
non‐CSCs (if they are not eradicated) can regenerate CSCs and renew
the growth of tumor (Gupta et al., 2011). Normal stem cells can be
engineered genetically for delivery of therapeutically relevant
molecules effective for targeting CSCs. For example, neural stem cells
can be engineered for secretion of IL‐4 for targeting CSCs and,
therefore, regressing the progression of tumors (Vescovi et al., 2006).
6.2 | Modalities to overcome chemo‐ and/or
radioresistance of CSCs
There are some modalities to make CSCs sensitive to
chemo/radiotherapy. First, targeting CSC extrinsic factors, including
suppression of extrinsic signaling pathways, disruption of the TME or
F IGURE 4 Cross‐talking between cancer stem cells (CSCs) with other cells within the tumor microenvironment (TME). CSCs have positive
interactions with adipose‐derived stem cells (ADSCs), cancer‐associated fibroblasts (CAFs), macrophage type 2 (M2) cells, regulatory T cells
(Tregs), T helper (Th)17 and endothelial cells (ECs), while they have negative cross‐talking with cytotoxic T lymphocytes (CTLs). COX2:
cyclooxygenase 2; CXCL12: CXC motif ligand 12; FGF: fibroblast growth factor; HGF: hepatocyte growth factor; IFN: interferon; ISG:
interferon‐stimulated gene; NO: nitric oxide; OPN: osteopontin; PGE2: prostaglandin E2; TGF‐β: transforming growth factor‐β; VEGF: vascular
endothelial growth factor
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the CSC niche within the TME is one of the promising approaches for
elimination of the cells. Targeting dominant tumorigenic signaling
within the TME is critical to control therapy resistance in CSCs (Lytle
et al., 2018). This is because of the crucial implication of the
environmental cues derived from TME in the stemness of CSCs (Ex,
IL‐17; Xiang et al., 2015), reinstatement (dedifferentiation) of non‐
CSCs into CSCs (Ex, TGF‐β), resistance of CSCs (Cazet et al., 2018;
Medema, 2017) and in the metastasis of the cells (Ex, cyclooxygenase
2 [COX2]/prostaglandin E2 [PGE2]; Wang et al., 2015). To reach this
purpose, one or more of three available modalities can be pursued for
dampening the activity of tumorigenic cells within the tumor stroma:
their recruitment, activation, and cross‐talking. For example, inhibi-
tion of Hh signaling can suppress CAF activation, followed by
increased sensitivity of CSCs to chemotherapeutic drugs, as shown in
patients with breast cancer. CAFs, unlike cancer cells, have no
genomic instability, so they are less likely to acquire drug resistance
over time, making the cells proper targets for cancer combination
therapy (Cazet et al., 2018). CAFs secrete OPN (Lenos et al., 2018)
that is accumulated in CSCs, and there is evidence in hepatocellular
carcinoma (HCC) that CSCs with high OPN levels are more sensitive
to inhibitors of DNA methylation like 5‐azacytidine (Gao et al., 2018).
CAFs also secrete high amount of TGF‐β to the TME (Farhood et al.,
2018). Inhibition of TGF‐β signaling using LY364947 is reported to
increase the rate of CSC penetration to nanoparticles facilitating CSC
therapy (Zuo et al., 2016). Another example is that interaction
between M2 cells (another key cells within the TME) favors release
of STAT3 to the TME (Najafi, Hashemi Goradel et al., 2018) that
further renders CSC immunosuppressive profile (D. Zhang et al.,
2018) and induces radioresistance in the cells (Y. Shi et al., 2018).
Therefore, modalities within the TME could cause optimistic out-
comes in increasing the rate of responsiveness to the chemo/
radiotherapy and thereby reducing tumor burden, increasing patient
survival and possibly abolishing a chance of tumor recurrence.
Hypoxia is known as a common feature of the TME (Lan et al.,
2018) that is induced diversely after treatment with chemo/radio-
therapy (Dianat‐Moghadam et al., 2018). Hypoxia is associated with
F IGURE 5 Targeting cancer stem cells (CSCs) for cancer therapies. There are a number of approaches for addressing CSCs, including
targeting extrinsic factors, intrinsic factors, and control of CSC cell division. For extrinsic factors, making a control over cellular recruitment,
activation or cross‐talking within the tumor microenvironment (TME), or controlling hypoxia in this milieu is beneficial for reducing the number
of CSCs and their stemness. For intrinsic factors, suppression of oncogene inherited markers such MET or silencing DNA binding (ID)
transcriptional regulators can offer effective strategies for targeting CSCs. In addition, because heterogeneity in the CSC number per tumor is
considered as an essential determinant of cancer control after therapy, switching CSCs division toward an asymmetric manner using inhibitor of
related mediators, such as insulin‐like growth factor 1 (IGF1) could increase the efficacy of therapy. ABC: ATP‐binding cassette; ALDH:
aldehyde dehydrogenase; miRNAs: microRNAs; TGF‐β: transforming growth factor‐β
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therapy resistance in CSCs through activation of EMT genes (Lytle
et al., 2018) and autophagy process (Dianat‐Moghadam et al., 2018).
There is a direct relation between hypoxia and ECM composition,
which plays a key function in the emergence of CSCs (Marquardt
et al., 2018). Hypoxia‐inducible factor 1 (HIF‐1) and HIF‐2α are main
of hypoxia response in cancers. Activation of HIF‐1α by PI3K/AKT is
contributed to the expression of the EMT modulator TWIST1. HIF2α
functions as an activator of stemness genes Sox2, OCT4 and CD44,
among other (El Hout et al., 2018). CSCs have protective autophagy in
which they have a controlled range of autophagy required for
promoting their survival (Talukdar et al., 2018b). Hypoxia through
activation of autophagy process in CSCs is able to compensate ATP
deficiency, to provide metabolic nutrients, to promote survival in
CSCs, and to upregulate stemness genes (Dianat‐Moghadam et al.,
2018). The protective autophagy process in CSCs is for promoting
their resistance to anoikis that is considered as a form of programmed
cell death occurring after detachment of anchorage‐dependent cells
from the ECM (Talukdar et al., 2018a). Autophagy in CSCs can be
targeted by either inhibition of this process (Baquero et al., 2018) or
by its overactivation (Talukdar et al., 2018b). There is compelling
evidence for the efficacy of autophagy inhibitors for suppression of
CSCs in tumors like leukemia (Baquero et al., 2018). Overactivation
of autophagy can initiate a toxic autophagy process reducing the rate
of survival in CSCs (Talukdar et al., 2018b). Hypoxia‐inducible effect
on autophagy and further replenishing for ATP is related to the efflux
of drugs from CSCs, as mentioned before. It is also important to note
that chemotherapeutic agent when encounter a hypoxic condition
could diversely cause CSC enrichment through regulation mitogen‐
activated protein kinase signaling. This regulation is mediated by the
inhibition of ERK and activation of p38 signaling for respective
induction and stabilization of pluripotency factors in the CSCs (Lu
et al., 2018). Radiotherapy also indirectly induces expression of HIF‐
1α (X. Chen et al., 2018). Therefore, it is suggested to apply a
reoxygenation strategy or using HIF‐1 inhibitors in combination with
chemotherapy or radiotherapy to induce chemo/radio sensitization
and abolish CSC enrichment (X. Chen et al., 2018; Lu et al., 2018). The
reoxygenation possibly allows differentiation of CSCs. When the cells
are committed to differentiation, they cannot initiate tumor growth
because the cells in the stem cell state can fuel tumor growth (not
after differentiation) (Baumann et al., 2008; Medema, 2017). In
addition, when committed to differentiation, CSCs would take out of
their stem cell pool and thereby will be prone to be killed by the
application of therapeutic approaches (Baumann et al., 2008).
It seems that targeting TME would offer optimistic outcomes for
suppressing both CSCs and non‐CSCs and their interplay. Targeting
both of the cell types is important for effective therapeutic purposes
because there is evidence for the niche refilling by new CSCs derived
from cancer cells after the killing of preexisting CSCs in colon cancer
(Shimokawa et al., 2017). Modulation within the TME would hamper
non‐CSC‐to‐CSC conversion that probably provides a proper
combination with drugs sensitizes CSCs. The niche containing CSCs
and the vascular bed can be disrupted to expose both CSCs and
cancer cells to the cytotoxic effects of conventional chemotherapy
(Gilbertson & Rich, 2007). Increase in the sensitivity of CSCs to
chemotherapeutic drugs can be pursued using nonsteroid anti‐
inflammatory drugs (NSAIDs) like aspirin. Aspirin induces the fas
ligand (FasL) pathway of apoptosis in CSCs of patients with CRC
without affecting non‐CSCs, so NSAIDs can possibly be served as
effective adjuvant therapy for cancer (Z. Chen et al., 2018). Although
efficacy of NSAIDs in tumor‐targeted therapies has been approved,
for potentiating the effectiveness of cancer combination therapies
choosing proper chemotherapeutic drugs that are specific for a
tumor type is a preferred option.
CSC niche is a nutrient‐deprived milieu causing high dependency
of CSCs to mitochondrial oxidative phosphorylation (OXPHOS) to
meet the energy requirement of the cells (Hermann & Sainz, 2018).
CSCs highly rely on lipid metabolism to satisfy their energy demands
(Yi et al., 2018), so metabolic reprogramming of the TME or CSC
niche may be another strategy for reducing the number of these cells
(Hermann & Sainz, 2018). In addition, circadian clock in the TME
would make a control over the circadian dynamics of CSCs. This
regulation is probably important for inhibition of CSC overproduc-
tion. The CSC circadian dynamic explains presumable variations in
efficacy of anticancer drugs (Matsunaga et al., 2018). Therefore, to
make a regulation over TME and suppress cancer progression, it is
important to re‐establish circadian rhythm within this milieu
(Alvarez‐García, González, Alonso‐González, Martínez‐Campa &
Cos, 2013; Mortezaee, 2018).
Second, direct target of CSC intrinsic factors is another way to
overcome therapy resistance (Lytle et al., 2018). For example, MET
signaling can be targeted in CSCs to control their clonogenic features
by transforming them toward radiosensitive nonstem cells. MET
initiates signaling pathways in CSCs resulting in their increased DNA
repair and survival, and thereby fostering their radioresistance
(Comoglio et al., 2018; Lenos et al., 2018). Targeting Notch as a
factor for promoting self‐renewal and survival in CSCs is another
promising strategy to remove drug resistance in the cells (Shah et al.,
2018). Mutations in the p53 gene can bear a CSC phenotypic feature
in normal stem cells within tissues and organs, so knockdown of this
mutant p53 can reduce the frequency of the tumorigenic cells
(Koifman et al., 2018). For example, mutations in p53 may cause high
expression of CD44 in breast CSCs for the promotion of survival in
the cells (Bai et al., 2018). Developing monoclonal antibodies against
CD44 could be used as a promising strategy for the selective
elimination of self‐renewal potential in CSCs (Marquardt et al., 2018).
In prostate cancer, p53 is reported to contribute to suppression of
stemness and metastasis in CSCs via downregulation of CD51 in the
cells, so activation of CD51 could be a therapeutic target for
restricting progression of prostate cancer (Sui et al., 2018).
Targeting CSC markers by inserting apoptotic‐related genes to
the gene locus of the markers can also be hopeful. For example,
version of the suicide‐gene caspase‐9 can be inserted into the Lgr5
locus for elimination of Lgr5+ CSCs in human CRC (Hermann & Sainz,
2018). The next target could be on cysteine cathepsins that are
lysosomal peptidases upregulated in CSCs and are considered as
mediators of CSC resistance to apoptotic signals (Anja et al., 2018).
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Another approach to overcome CSC resistance to therapy is by
targeting MEK signaling through blocking its activators, such as B7‐
H3, a tumor‐promoting glycoprotein overexpressed in various types
of cancers and is related to drug resistance through enrichment of
CSC population (Z. Liu et al., 2018). Stemness markers can be a target
for hormonal therapy like melatonin, a potent oxidative/antioxidative
hormone with known anticancer properties (J.H. Lee et al., 2018;
Mortezaee & Khanlarkhani, 2018). Melatonin through activation of
melatonin receptor 1 (MT1) receptor can suppress stemness and
promote sensitivity of CSCs to chemotherapy, as reported in brain
cancer (H. Lee, Lee, Jung, Shin, & Kim, 2018). The stemness markers
can be activated in cancer cells after exposure to environmental
insults. For example, it has been proven in pancreatic cancer that
exposure to nicotine could activate RAF1 in cancer cells for the
promotion of their stemness (Nimmakayala et al., 2018), so it is
suggestive to avoid exposure to environmental hazards to prevent
the progression of cancer in affected patients. β‐catenin signaling can
be suppressed in CSCs using inhibitors for increasing the efficacy of
chemotherapeutic drugs. For example, suppression of β‐catenin using
inhibitors for cyclin‐dependent kinase 1 (CDK1; a protein kinase
important for cellular transitions of G1/S and G2/M phases) is
reported to overcome the resistance of CSCs to sorafenib in HCC
(Wu et al., 2018). A point to consider is that the β‐catenin pathway is
indirectly reactivated after prolong application of PI3K inhibitors for
patients with cancer (evidenced in HCC), so percussion is necessary
for the administration of such therapies (F. Liu, Wu, Jiang, Qian, &
Gao, 2018). Moreover, microRNA (miRNA) contribution to the
regulation of CSC biology is needed to be under consideration.
MiRNAs mediate aberrant epigenetic regulation over CSCs and play
important roles in CSC‐related EMT, metastasis, angiogenesis, and
drug resistance. To do these functions, miRNAs regulate p53 gene
expression profile, and that they have interactions with the key
signaling pathways in CSC tumorigenesis such as WNT, TGF‐β, and
PI3K/AKT. Identifying these miRNAs in cancers and targeting them is
important not only for designing therapeutic protocols but also for
diagnosis of cancer. For example, miRNA‐21 has been identified as a
biomarker for the diagnosis of CRC (De Robertis et al., 2018), and
enforced expression of miR‐34a (a p53 target) in prostate cancer can
inhibit clonogenic expression of CSCs and suppression of their
regeneration and related metastasis (C. Liu et al., 2011). Small
interfering RNA could also be applied. For example, siAKT2 is
reported to be effective in impairing CSC‐mediated breast tumor
recurrence (Rafael et al., 2018).
Third, as it has been discussed before, disruption of asymmetric
division in CSCs occur upon tumor progression, which is for
expanding the number of the cells within a tumor (Lytle et al.,
2018). Heterogeneity in the CSC number per tumor is an essential
determinant of cancer control following therapy (Baumann et al.,
2008). Therefore, increase in the asymmetric division can be served
as an approach to halt the aggressive progression of cancer (Lytle
et al., 2018). For example, for mouse lung cancer, the relevance
between high insulin‐like growth factor 1 with the initiation of CSC
TABLE 2 Cancer type dependent therapeutic targeting against cancer stem cells (CSCs) harvested from human cancerous tissues
Agent type Mechanism Cancer type References
MiR‐4319 Regulation of CSC tumorigenesis and self‐renewal Breast Chu et al. (2018)
MiR‐141 Suppression of prometastatic genes in CSCs Prostate C. Liu, Liu
et al. (2017)
Luteolin Luteolin is a common dietary flavonoid that acts through inhibition of WNT
signaling by upregulation of FZD6 transcription
Prostate Han et al. (2018)
MiR‐34a Direct repression of CD44 in CSCs Prostate C. Liu et al. (2011)
MiR‐18a‐5p Downregulation of HIF‐1α Lung X. Chen et al. (2018)
USP22 block Downregulation of ALDH1 Lung Yun et al. (2018)
BMS‐345541 BMS‐345541 is an NF‐κB inhibitor that suppresses EMT and apoptotic
resistance in CSCs
Lung Zakaria et al. (2018)
Regorafenib Potentiating the activity of the tumor suppressor miR‐34a Colon Cai et al. (2018)
MiR‐195‐5p Suppression of CSC stemness CRC Jin et al. (2018)
Ibrutinib Inactivation of BMX–STAT3 Glioma Y. Shi et al. (2018)
AMG232 MDM2 inhibitor. MDM2 is an E3 ubiquitin ligase that is responsible for
destabilization and negatively regulation of the p53 protein
Glioblastoma Her et al. (2018)
Anti‐ABCG2 ABCG2 is a transmembrane protein acting as ABC transporters for
unidirectional efflux of chemotherapeutic drugs
MM F. Shi et al. (2018)
WYC‐209 WYC‐209 is a synthetic retinoid that induces apoptosis in CSCs Melanoma, lung, and
breast
J. Chen et al. (2018)
ACR Suppression of the WNT/β‐catenin pathway in CSCs HCC Qin et al. (2018)
Note. ABC: ATP‐binding cassette; ACR: acyclic retinoid; ALDH: aldehyde dehydrogenase; BMX: bone marrow and X‐linked; CRC: colorectal cancer; CSC:
cancer stem cell; EMT: epithelial–mesenchymal transition; FZD6: frizzled class receptor 6; HCC: hepatocellular carcinoma; HIF‐1α: hypoxia‐inducible
factor‐1; MDM2: murine double minute 2 gene; MM: multiple myeloma; NF‐κB: nuclear factor of κB; STAT3: signal transducer and activator of
transcription 3; USP22: ubiquitin specific peptidase 22.
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self‐renewal from asymmetry to symmetry through activation of the
PI3K/AKT/β‐catenin and the subsequent recurrence of the tumor has
been elucidated (Li et al., 2018). So, acknowledging the roles of such
mediators or related pathways for cancers can provide a promising
approach for reducing the risk of tumor relapse.
Fourth, CSCs can be targeted by immunotherapeutic approaches
including immune checkpoint blockade (ICB), monoclonal antibodies,
vaccination, T cell therapy, and activation of innate immune responses,
such as NK cells (D. Zhang et al., 2018). CSCs have developed a myriad
of ways to circumvent a possible attack from the immune system,
including loss of cancer antigen expression, activation of oncolytic
pathways, and promotion of an immunosuppressive milieu and (epi)
genetic alterations that cause their reduced recognition by the
immune system (D. Zhang et al., 2018). These immunotherapeutic
approaches con offer a potential targeting for increasing the sensitivity
of CSCs to chemo‐ and/or radiotherapy. ICB approaches, for example,
can revoke the activity of CSCs and other immunosuppressive cells
within the TME. CSCs (Dianat‐Moghadam et al., 2018) and cancer cells
(Mortezaee, 2018) produce programmed death‐1 ligand (PD‐L1), and
its receptor PD‐1 is expressed by Tregs (Zappasodi et al., 2018). CSCs
also release PD‐1 to their niche (D. Zhang et al., 2018). PD‐L1 could
cause exhaustion and dysfunction of effector T cells (Du et al., 2018)
and restriction of CSC immune escaping. A point here is to apply
immunotherapeutic approaches for unique CSC markers and antigens
preferentially expressed by the cells (D. Zhang et al., 2018). In Table 2,
agents used for targeting CSCs in various human cancers has been
described focusing on the mechanisms involved in exerting their
therapeutic efficacy, and in Figure 6, strategies for targeting CSCs are
summarized.
7 | CONCLUSION AND PERSPECTIVE
The information provided in this review is mostly from the evaluation
of CSCs in vitro and from xenograft data, and it followed a rather
holistic overview toward cancer, so it has not pertained to all types of
cancers. Human tumoral tissues engrafted to the immune compro-
mised animals may experience different responses to the environ-
mental cues from animals, and that the level of functionality of CSCs
is possibly differ from one cancer to another, or even the grade of
one specific tumor may cause a noticeable effect on CSC function-
ality. In fact, tumors at early stages have lower genetic aberrations,
lower TME potential to influence CSCs, and possibly fewer number of
the cells compared with the established tumors. CSCs from different
tissue origins exhibit different cell surface glycoproteins and have
diverse requirements for their growth and maintenance (Anja et al.,
2018). For targeting cancer in the clinic, there is an urgent need for
cancer type basis of CSC identification and sensitivity and selective
killing of the cells to expect more accurate responses, and due to the
existence of different population of CSCs within a type of tumor (da
Silva‐Diz et al., 2018), isolation of the cells must be carried out by
targeting different markers for the cells (not just one marker).
It is still unclear whether a CSC that can cause tumor initiation is
the same as a CSC that can cause tumor relapse after chemo/
radiotherapy. There are also burning issues regarding the density of
the cells and their spatial distribution. Although it has been reported
a high amount of the CSCs remained in residual tumors (Cazet et al.,
2018), the frequency of these cells for many tumors is low (almost
1/1,000 cells) demanding power purification approaches (that are not
yet extensively available) for isolation of the cells (Nguyen et al.,
2012), thereby limiting development of drugs and treatment
strategies (Takebe et al., 2011). In addition, it is unknown whether
markers discussed before have the properties of bona fide CSCs, and
that their specificity and the stability of expression in the CSCs over
time of exhibiting their stem‐like properties is another issue needing
further research to design therapeutic protocols more specifically on
the cells, as it is approved that inactivation of all CSCs is required for
permanent local cancer control (Baumann et al., 2008).
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